Vaccitech plc (NASDAQ:VACC – Get Rating) traded down 2.2% on Wednesday . The company traded as low as $2.18 and last traded at $2.25. 30,744 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 153,387 shares. The stock had previously closed at $2.30.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on the stock. Morgan Stanley dropped their price target on shares of Vaccitech from $19.00 to $16.00 and set an "overweight" rating for the company in a research report on Monday, August 15th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Vaccitech in a research report on Monday, November 14th.
Get
Vaccitech alerts:
Vaccitech Stock Down 2.2 %
The business's 50 day simple moving average is $2.64 and its two-hundred day simple moving average is $3.78. The stock has a market cap of $83.92 million, a P/E ratio of 7.03 and a beta of 0.10.
Vaccitech (NASDAQ:VACC – Get Rating) last posted its earnings results on Thursday, November 10th. The company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.54. The company had revenue of $6.17 million for the quarter, compared to the consensus estimate of $5.43 million. As a group, research analysts forecast that Vaccitech plc will post 0.27 earnings per share for the current fiscal year.
Institutional Trading of Vaccitech
A hedge fund recently bought a new stake in Vaccitech stock. Alphabet Inc. purchased a new stake in shares of Vaccitech plc (NASDAQ:VACC – Get Rating) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,513,644 shares of the company's stock, valued at approximately $4,844,000. Alphabet Inc. owned about 4.06% of Vaccitech at the end of the most recent quarter. Institutional investors own 12.86% of the company's stock.
About Vaccitech
(Get Rating)
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.
Featured Articles
- Get a free copy of the StockNews.com research report on Vaccitech (VACC)
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- Top 10 Searched Stocks on MarketBeat All-Access
- 3 Dividend Kings With Royally Good Upside
- Institutions Sell The Rallies In Toll Brothers Stock
- Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Receive News & Ratings for Vaccitech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccitech and related companies with MarketBeat.com's FREE daily email newsletter.
